Kiromic BioPharma, Inc. (KRBPQ)
OTCMKTS
· Delayed Price · Currency is USD
0.1100
+0.0480 (77.42%)
May 7, 2025, 4:00 PM EDT
Kiromic BioPharma Employees
Kiromic BioPharma had 44 employees as of December 31, 2024. The number of employees increased by 9 or 25.71% compared to the previous year.
Employees
44
Change (1Y)
9
Growth (1Y)
25.71%
Revenue / Employee
n/a
Profits / Employee
-$105,136
Market Cap
172.80K
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Endo Inc. | 3,116 |
Tian'an Technology Group | 8 |
Glass House Brands | 374 |
CytoDyn | 9 |
Elite Pharmaceuticals | 64 |
Northwest Biotherapeutics | 25 |
American Oncology Network | 1,914 |
Silence Therapeutics | 116 |
Kiromic BioPharma News
- 2 months ago - Kiromic BioPharma Reports Patient 4 in Deltacel-01 Clinical Trial Reaches 10-Month Progression-Free Survival - Business Wire
- 3 months ago - Kiromic BioPharma Reports Tumor Volume Decrease in Two Patients Enrolled in Deltacel-01 - Business Wire
- 5 months ago - Kiromic BioPharma Reports 32% Decrease in Tumor Volume Eight Months Post-Treatment in Fourth Patient Enrolled in Deltacel-01 - Business Wire
- 5 months ago - Kiromic BioPharma Announces Settlement of Previously Disclosed SEC Investigation - Business Wire
- 5 months ago - SEC Charges Kiromic BioPharma and Two Former C-Suite Executives with Misleading Investors about Status of FDA Reviews - Newsfile Corp
- 7 months ago - Kiromic BioPharma Reports Favorable Ongoing Clinical Results From Fourth and Sixth Patients Enrolled in Deltacel-01 - Business Wire
- 7 months ago - Kiromic BioPharma Reports Favorable 10-Month Follow-Up Results for the First Patient Treated in its Deltacel-01 Clinical Trial - Business Wire
- 8 months ago - Kiromic BioPharma Activates the University of Arizona Cancer Center as the Fifth Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 Trial - Business Wire